Recovery
Aviptadil
Also called VIP, RLF-100
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the EU, only as a fixed combination with phentolamine.
The human evidence for Aviptadil used the intravenous route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Quick start
Aviptadil at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 25–100 mcg per administration
- How often
- Every day
- Where
- Intravenous (clinical setting)
- Time to steady level
- ~0 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Aviptadil describe 25–100 mcg per administration. Descriptive only, not a recommendation.
Minutes-scale in plasma; VIP is degraded rapidly, so the decay chart is largely illustrative here.
A vasoactive intestinal peptide (VIP). The human evidence is intravenous, with additional inhaled studies, and it is licensed in the EU only as a fixed combination with phentolamine, given by injection. No subcutaneous dose-ranging schedule is established, so no schedule table is shown and the vial size shown is nominal.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 0.90× single dose
- Time to steady state
- 0hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Aviptadil/phentolamine combination-injection literatureAviptadil (VIP) is licensed in the EU only as a fixed combination with phentolamine, given by injection.
- RLF-100 (aviptadil) intravenous and inhaled studiesHuman studies used intravenous infusion and inhalation; no subcutaneous schedule was fixed.